0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Cardiotoxicity as a Possible Side Effect of Statins

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          According to current views, statins have a wide range of beneficial effects (lipid and non-lipid) on the cardiovascular system, so they are one of the most commonly used drugs for the prevention and management of patients with cardiovascular diseases. However, it is important to note that information about many beneficial effects of statins is contradictory. In addition, a number of side effects of statins, in particular, myotoxicity, hepatotoxicity, diabetogenic property, etc., may limit the possibility of using statins or even force doctors to cancel these drugs. Also, some concerns are caused by recent studies reporting cardiotoxicity of statins and increased serum concentrations of biomarkers of myocardial damage (highly sensitive cardiac troponins (hs-cTns)) in patients taking statins. This article discusses in detail the possible mechanisms of cardiotoxicity of statins and outlines the directions for further research in this area.

          Related collections

          Most cited references93

          • Record: found
          • Abstract: found
          • Article: not found

          Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

          Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. Whether it prevents cardiovascular events is uncertain.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

            Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high-intensity statin therapy.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Fourth universal definition of myocardial infarction (2018)

                Bookmark

                Author and article information

                Contributors
                Role: Academic Editor
                Journal
                Rev Cardiovasc Med
                RCM
                Reviews in Cardiovascular Medicine
                IMR Press
                2153-8174
                1530-6550
                11 January 2023
                January 2023
                : 24
                : 1
                : 22
                Affiliations
                [1] 1Department of Histology and Embryology, Samara State Medical University, 443099 Samara, Samara Region, Russia
                [2] 2Department of Cardiology and Cardiovascular Surgery, Samara State Medical University, 443099 Samara, Samara Region, Russia
                [3] 3Research Institute of Cardiology, Samara State Medical University, 443099 Samara, Samara Region, Russia
                Author notes
                *Correspondence: alekseymichailovich22976@ 123456gmail.com (Aleksey Chaulin)
                Author information
                https://orcid.org/0000-0002-2712-0227
                Article
                S1530-6550(22)00777-3
                10.31083/j.rcm2401022
                11270446
                39076865
                987f230b-466d-4591-b154-e2ebbdadca5d
                Copyright: © 2023 The Author(s). Published by IMR Press.

                This is an open access article under the CC BY 4.0 license.

                History
                : 12 October 2022
                : 17 November 2022
                : 21 November 2022
                Categories
                Review

                side effect,cardiotoxicity,statins,cardiac troponins,highly sensitive cardiac troponins,mechanisms

                Comments

                Comment on this article